RFK Jr. Locks In Permanent Chiefs for FDA Drug, Vaccine and Tobacco Divisions

The FDA finally has permanent leadership in three of its most contentious departments. Health and Human Services Secretary Robert F. Kennedy Jr. announced on Tuesday, September 8, that three officials who had been running divisions in an acting capacity are now the permanent directors, according to the Department of Health and Human Services.

Dr. Michael Davis takes over the Center for Drug Evaluation and Research, the FDA's largest division and the one that decides whether prescription and over-the-counter drugs are safe and effective. Karim Mikhail becomes permanent director of the Center for Biologics Evaluation and Research, which oversees vaccines. Bret Koplow was made permanent head of the Center for Tobacco Products, according to HHS and confirmed by the Associated Press.

"We are building an FDA that moves faster, demands excellence, and delivers results for the American people," Kennedy said in the HHS statement. "These leaders will drive reforms needed to confront our nation's most serious health challenges and strengthen American leadership in medical innovation."

A Revolving Door Finally Stops Spinning

These appointments only exist because of a string of departures. Dr. Tracy Beth Hoeg ran the drug center before Davis and says she was fired in May, according to the Associated Press. Her short tenure focused on scrutinizing antidepressants, COVID-19 shots, and drugs prescribed to children.

Davis isn't new to the building. He previously led the FDA's psychiatric drug division, left briefly to work at a nonprofit developing psychedelic drugs, then returned to the agency as a deputy director last year, according to the Associated Press. Now, as the top drug regulator, he's positioned to oversee reviews of psilocybin, MDMA, and LSD for psychiatric use. Both Trump and Kennedy have pushed for faster reviews of these treatments.

On the vaccine side, Mikhail spent more than 20 years at Merck & Co. and held executive roles at other pharmaceutical firms internationally, according to the Epoch Times. He holds a business degree from Paris and a pharmaceutical sciences degree from Cairo University. He joined the FDA last spring and stepped into the acting vaccine chief role after Dr. Vinay Prasad's exit.

Prasad's departure involves conflicting accounts from different sources. The Associated Press reports Prasad stepped down in March, citing broader controversies over vaccines, gene therapies and biotech drugs, and notes it was his second time leaving the role in under a year following complaints from biotech executives and patient groups over rare-disease drug handling. The Epoch Times, by contrast, places his exit at the end of April and ties it specifically to a clash with pharmaceutical companies and lawmakers over Moderna's new mRNA flu vaccine. The sources differ on timing and specific cause.

What's not in dispute: Prasad, working alongside former Commissioner Dr. Marty Makary, built stringent new requirements forcing vaccine-makers to run lengthy new studies before updated COVID-19 shots could be approved for healthy adults and children. Makary himself resigned in May after months of complaints from health industry executives, anti-abortion activists and tobacco companies, according to the Associated Press.

The Fair Concern, and the Other Side

Consumer groups, physicians and congressional Democrats have raised concerns about the pace and direction of policy shifts across all three of these centers, according to the Associated Press, particularly around vaccine access and the added hurdles for updated COVID shots. Rapid leadership turnover and stricter approval requirements can create uncertainty for drugmakers and patients trying to plan around FDA timelines.

Kennedy and his team argue the agency needed a shake-up after years of what they characterize as industry-friendly rubber-stamping, and that permanent leadership, even leadership pursuing more aggressive scrutiny, beats a parade of acting directors with no mandate to make lasting policy. Four major departures in roughly a year and two commissioners' worth of controversy indicate significant internal turbulence. Whether Kennedy's replacements stabilize the agency or restart the cycle remains unclear.

HHS also pointed to a fourth new leadership post focused on artificial intelligence and regulatory modernization as part of Tuesday's announcement, though the agency's public statement did not name who fills that role. The most immediate test of the new lineup comes soon: Davis now oversees a backlog of psychedelic drug applications that Trump and Kennedy have both said they want moved faster, and how those reviews play out will be the first real measure of whether "faster" means safer or just faster.